Stenke, Leif

Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML

Warfvinge, R., Geironson, L., Sommarin, M. N. E., Lang, S., Karlsson, C., Roschupkina, T., Stenke, L., Stentoft, J., Olsson-Strömberg, U., Hjorth-Hansen, H., et al. (2017) · Blood

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 154

2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia

Apperley, J. F., Milojkovic, D., Cross, N. C. P., Hjorth-Hansen, H., Hochhaus, A., Kantarjian, H., Lipton, J. H., Malhotra, H., Niederwieser, D., Radich, J., et al. (2025) · Leukemia

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 139

First global consensus for evidence-based management of the hematopoietic syndrome resulting from exposure to ionizing radiation

Dainiak, N., Gent, R. N., Carr, Z., Schneider, R., Bader, J., Buglova, E., Chao, N., Coleman, C. N., Ganser, A., Gorin, C., et al. (2011) · Disaster Medicine and Public Health Preparedness

Effects of Radiation ExposureDisaster Response and Management

Cited by 107

European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission

Mahon, F.-X., Pfirrmann, M., Dulucq, S., Hochhaus, A., Panayiotidis, P., Almeida, A., Mayer, J., Hjorth-Hansen, H., Janssen, J. J. W. M., Mustjoki, S., et al. (2024) · Journal of Clinical Oncology

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 71

Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR—final report from AFTER-SKI

Richter, J., Lübking, A., Söderlund, S., Lotfi, K., Markevärn, B., Själander, A., Stenke, L., Deneberg, S., Ahlstrand, E., Myhr-Eriksson, K., et al. (2021) · Leukemia

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 27

Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib – interim results from the DAstop2 trial

Flygt, H., Söderlund, S., Richter, J., Saussele, S., Koskenvesa, P., Stenke, L., Mustjoki, S., Dimitrijevic, A., Stentoft, J., Majeed, W., et al. (2024) · Leukemia

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 18

Loss in Overall and Quality‐Adjusted Life Expectancy for Patients With Chronic‐Phase Chronic Myeloid Leukemia

Chen, E. Y., Dahlén, T., Stenke, L., Björkholm, M., Hao, S., Dickman, P. W., & Clements, M. S. (2025) · European Journal of Haematology

Health Systems, Economic Evaluations, Quality of LifeChronic Myeloid Leukemia Treatments

Cited by 13

Long‐term tolerability and efficacy after initial PegIFN‐α addition to dasatinib in CML‐CP: Five‐year follow‐up of the NordCML007 study

Flygt, H., Söderlund, S., Stentoft, J., Richter, J., Koskenvesa, P., Mustjoki, S., Majeed, W., Lübking, A., Dreimane, A., Markevärn, B., et al. (2021) · European Journal of Haematology

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 11